Detalles de la búsqueda
1.
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Cell
; 173(2): 400-416.e11, 2018 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29625055
2.
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Cell
; 173(2): 291-304.e6, 2018 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29625048
3.
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.
Cell
; 158(4): 929-944, 2014 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25109877
4.
ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer.
Proc Natl Acad Sci U S A
; 120(52): e2313693120, 2023 Dec 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38117852
5.
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Breast Cancer Res
; 25(1): 117, 2023 10 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37794508
6.
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Breast Cancer Res Treat
; 199(2): 281-291, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37029329
7.
Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments.
BMC Cancer
; 21(1): 212, 2021 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33648460
8.
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Breast Cancer Res
; 19(1): 99, 2017 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28851423
9.
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Breast Cancer Res
; 19(1): 107, 2017 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28893315
10.
Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Breast Cancer Res Treat
; 161(1): 41-50, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815749
11.
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Breast Cancer Res Treat
; 155(3): 521-30, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26875185
12.
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Breast Cancer Res
; 17: 73, 2015 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-26021444
13.
Expression profiling of circulating tumor cells in metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 121-31, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25432738
14.
Subtype and pathway specific responses to anticancer compounds in breast cancer.
Proc Natl Acad Sci U S A
; 109(8): 2724-9, 2012 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22003129
15.
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
NPJ Breast Cancer
; 10(1): 17, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38409268
16.
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Clin Cancer Res
; 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38470545
17.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Clin Cancer Res
; 30(4): 729-740, 2024 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38109213
18.
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Front Oncol
; 13: 1192208, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37384294
19.
Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
JCO Precis Oncol
; 7: e2200670, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738542
20.
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
Nat Cancer
; 4(2): 240-256, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759733